Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)
Analysis of Revenues
Advanced level
Revenues as Reported
Regeneron Pharmaceuticals Inc., Income Statement, Revenues
US$ in thousands
| 12 months ended | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 7,863,400 | 6,710,800 | 5,872,227 | 4,860,427 | 4,103,728 |
Based on: 10-K (filing date: 2020-02-07), 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11).
| Item | Description | The company |
|---|---|---|
| Revenues | Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). | Regeneron Pharmaceuticals Inc.’s revenues increased from 2017 to 2018 and from 2018 to 2019. |